Multi-Institutional Inter-SPORE Prostate Biomarker Study
The Inter-SPORE Prostate Biomarkers Study (IPBS) was established to prospectively collect
and analyze biological specimens to predict and validate outcomes after treatment for
prostate cancer. The study population will consist of patients scheduled to receive standard
of care therapy for localized prostate cancer, either radical prostatectomy (RP) or
radiation therapy (XRT; includes external beam radiation, brachytherapy, or both). Seven
hundred (700) patients (350 RP, 350 XRT) will be recruited from 11 SPORE sites over a
two-year interval. We will collect serum, plasma, lymphocytes, and prostate tissue samples
for distribution to collaborating biomarker validation sites at other prostate SPOREs, along
with clinical and epidemiologic data.
Observational
Observational Model: Case Control, Time Perspective: Prospective
Coll & contrib bio spec to Inter-SPORE Prostate Biomarker Study men with clinical localized prostate ca sched to get standard of care therapy for localized prost ca, either radical prostatectomy, RT therapy
pre-treatment and at yearly intervals during follow-up.
No
James Eastham, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
07-053
NCT00574899
May 2007
May 2011
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
UCLA | Los Angeles, California 90095 |